Fujifilm Diosynth Biotechnologies unveils strategic customer-focused business structure

FUJIFILM Diosynth Biotechnologies, A CDMO for biologics, vaccines, advanced therapies and oncolytic viruses, has revealed a new SBU structure (strategic business unit). This new unit was created to help provide clients with a service to aid their organisation and help them supply a world-class performance to their customers through aligning unique service offerings and manufacturing capacities.

The large-scale SBU will be led by Kenneth Bilenberg and is designed to meet the needs of clients who need access to high-volume cell culture, utilizing multiples of 20,000 L bioreactors. The small-scale SBU, led by Lee Kingsbury, is more focused on providing support for clients with pre-clinical, early clinical phase I and II, and late clinical phase III. This SBU will also help clients with progressing to the approval and production of their products. The production volume utilises bioreactors ranging from 200 L to 2,000 L as well as single-use manufacturing systems.

Toshi Ida, the corporate vice president of FUJIFILM Corporation and chairman of FUJIFILM Diosynth Biotechnologies, has said “We are confident this new structure will help to advance our customers’ goals while also creating new, exciting opportunities for growth”. This new establishment will be supported by a new strategy and executive office, where Peter Dam Madsen will be appointed vice president